quinazolines has been researched along with Squamous Cell Carcinoma of Head and Neck in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 55 (93.22) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, BC; Cho, BC; Heo, SG; Hong, MH; Kim, HR; Lee, JH; Lim, SM | 1 |
| Lang, L; Teng, Y | 1 |
| Clement, PM; Cohen, EEW; Cupissol, D; de Souza Viana, L; Fayette, J; Gauler, T; Geng, Y; Geoffrois, L; Guigay, J; Haddad, R; Keilholz, U; Kornek, G; Licitra, L; Machiels, JP; Melichar, B; Rauch, D; Ribaldo Nicolau, U; Rolland, F; Tahara, M; Vermorken, J; Zanetta-Devauges, S; Zografos, E | 1 |
| Lang, L; Shay, C; Teng, Y; Wang, X; Xiong, Y; Zhao, X | 1 |
| Amendt, C; Blaukat, A; Dahmen, H; Fuchss, T; Grombacher, T; Kirkin, V; Pehl, U; Sirrenberg, C; Vassilev, LT; Wilm, C; Zenke, FT; Zimmermann, A | 1 |
| Akashi, M; Fukuoka, T; Hasegawa, T; Kakei, Y; Kashin, M; Sasaki, R; Teraoka, S; Yamaguchi, A | 1 |
| Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X | 1 |
| Burtness, B; Clement, PM; Cohen, EEW; Cong, XJ; Del Campo, JM; Dupuis, N; Ehrnrooth, E; Fayette, J; Gauler, T; Geoffrois, L; Gibson, N; Grau, JJ; Guigay, J; Haddad, RI; Krämer, N; Licitra, LF; Machiels, JH; Mailliez, A; Merlano, MC; Solca, F; Tahara, M; Vermorken, JB | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J | 1 |
| Brands, RC; El-Mesery, M; Hartmann, S; Kübler, AC; Müller-Richter, UDA; Scheurer, MJJ; Seher, A | 1 |
| Chu, PL; Chua, KLM; Chua, MLK; Liang, ZG; Low, KP; Nei, WL; Poon, DJJ; Ramaswamy, B; Shihabuddeen, WA; Soo, KC; Thong, PSP; Yeo, ELL | 1 |
| Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A | 1 |
| Bhave, S; Bruno, PA; Datta, J; Lang, JC; Mapp, AK; Pan, Q; Piao, L; Su, T; Taylor, CE; Teknos, TN; Xie, X; Zhang, M | 1 |
| Case, AJ; Domann, FE; Fletcher, EV; Love-Homan, L; Miller, FJ; Raeburn, A; Schickling, BM; Simons, AL; Sobhakumari, A | 1 |
| Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A | 1 |
| Austin, MC; Bauman, JE; Chai, X; Hayes, DN; Kurland, BF; Martins, RG; Mendez, E; Parvathaneni, U; Sampath, S; Schmidt, R; Vaezi, A | 1 |
| Andrews, GA; Byers, LA; Fooshee, DR; Frederick, MJ; Galer, C; Hah, JH; Heymach, J; Jasser, SA; Kim, E; Milas, ZL; Myers, JN; Papadimitrakopoulou, V; Pickering, CR; Sano, D; William, WN; Zhao, M | 1 |
| Ferrarotto, R; Gold, KA | 1 |
| Gauler, TC; Harbeck, N; Solca, F | 1 |
| Bansal, N; Center, B; Fetrow, JS; Furdui, CM; Kuremsky, JG; Marrs, GS; Mims, J; Olex, AL; Porosnicu, M; Qian, J; Tsang, AW; Wani, R; Yin, L; Zhao, W | 1 |
| Blackman, A; Clement, PM; Cohen, EEW; Cupissol, D; Degardin, M; Del Campo, JM; Ehrnrooth, E; Fayette, J; Hitt, R; Seiwert, TY; Zhang, W | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Corsten, M; Dayekh, K; Dimitroulakos, J; Johnson-Obaseki, S; Sekhon, HS; Villeneuve, PJ; Weberpals, JI | 1 |
| Baay, M; Boeckx, C; Deschoolmeester, V; Lardon, F; Limame, R; Op de Beeck, K; Pauwels, P; Peeters, M; Specenier, P; Van Camp, G; Vermorken, JB; Wouters, A; Zwaenepoel, K | 1 |
| Chen, CR; Cohen, EW; Frank, SJ; Heymach, JV; Hirsch, FR; Jimeno, A; Lin, H; Lowe, ES; Myers, JN; Nedzi, L; Papadimitrakopoulou, VA; Raben, D; Tran, HT; Vasselli, JR | 1 |
| Bourhis, JP; Burtness, B; Cohen, EE; Harrington, KJ; Vermorken, JB | 1 |
| Baum, A; Cohen, EE; Grushko, TA; Hardeman, A; Liu, J; Olopade, OI; Solca, F; Soneru, C; Young, NR | 1 |
| Atoyan, R; Bauman, JE; Burtness, B; Colevas, AD; Galloway, TJ; Gilbert, J; Jimeno, A; Ma, AW; Mehra, R; Raben, D; Saba, NF; Wang, J; Wirth, LJ | 1 |
| Espinosa-Cotton, M; Koch, AT; Love-Homan, L; Simons, AL; Stanam, A | 1 |
| Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP | 1 |
| Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H | 1 |
| Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
| Bourhis, J; Economopoulou, P; Psyrri, A | 1 |
| Ahmed, N; Amonkar, M; Biswas-Baldwin, N; Bourhis, J; D'Cruz, A; D'Onofrio, I; Dietzsch, S; Dubinsky, P; El-Hariry, I; Ellis, C; Farrell, J; Franklin, N; Harrington, K; Holeckova, P; Horvath, Z; Jain, M; Legenne, P; Manikhas, G; Mehanna, H; Netherway, T; Santillana, S; Sun, Y; Temam, S; Wang-Silvanto, J; Wissel, P | 1 |
| Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM | 1 |
| Specenier, P; Vermorken, J | 1 |
| Bagley, S; Bauml, J; Cohen, RB; Hayes, DN; Hwang, WT; Langer, C; Olson, JG; Weiss, JM | 1 |
| Banno, E; de Velasco, MA; Fujita, Y; Hamada, S; Hayashi, H; Nakahara, H; Nakamura, Y; Nishio, K; Nutahara, K; Okegawa, T; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S | 1 |
| Baba, Y; Fujii, M; Kato, Y; Maeda, T; Suzuki, A; Takada, S | 1 |
| Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Chen, C; D'Cruz, AK; Fijuth, J; Gregoire, V; Hamoir, M; Julka, PK; Kane, M; Kawecki, A; Korzeniowski, S; Kumar, RR; Machiels, JP; Prasad, S; Raben, D; Radosevic-Jelic, L; Sellers, MV; Tchakov, I; Wang, HM | 1 |
| Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S | 1 |
| Arnold, W; Beck, C; Boulesteix, AL; Knopf, A; Margraf, J; Pickhard, AC; Pigorsch, S; Piontek, G; Reiter, R; Scherer, EQ; Schlegel, J; Stark, T | 1 |
| Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG | 1 |
| Agulnik, M | 1 |
| Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA | 1 |
| Aktolga, S; Blair, EA; Bozeman, J; Cohen, EE; Dancey, JE; Davis, DW; de Souza, JA; Khattri, A; Kozloff, MF; Kunnavakkam, R; Lingen, MW; Nattam, S; Seiwert, TY; Stenson, KM; Vokes, EE; Wong, SJ; Zhang, Y | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH | 1 |
| Grandis, JR; Quesnelle, KM; Ratay, MK; Wheeler, SE | 1 |
| Gooding, WE; Grandis, JR; Johnson, DE; Joyce, S; Li, C; Maxwell, J; Panahandeh, M; Sen, M; Thomas, SM; Wang, L | 1 |
| Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D | 1 |
| Ahsan, A; Bradford, CR; Chepeha, DB; D'Silva, N; Eisbruch, A; Helman, JI; Lawrence, TS; Nyati, MK; Ramanand, SG; Tsien, CI; Wolf, GT; Worden, FP | 1 |
| Cohen, EE; Grushko, T; Liu, J; Liu, W; Olopade, OI; Pierce, C; Seiwert, TY; Shen, C; Wei, TF; Young, NR | 1 |
| Barr, S; Cassell, A; Freilino, ML; Grandis, JR; Lee, J; Panahandeh, MC; Thomas, SM; Wang, L | 1 |
5 review(s) available for quinazolines and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Afatinib in the treatment of head and neck squamous cell carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Early Detection of Cancer; Head and Neck Neoplasms; Humans; Immunotherapy; Meta-Analysis as Topic; Methotrexate; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Papillomavirus Vaccines; Postoperative Care; Precision Medicine; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Therapies, Investigational | 2015 |
Afatinib in squamous cell carcinoma of the head and neck.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
19 trial(s) available for quinazolines and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Treatment Outcome; Young Adult | 2021 |
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Adherence and Compliance; Treatment Outcome | 2019 |
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Topics: Administration, Intravenous; Administration, Oral; Afatinib; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous Cell; Disease-Free Survival; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2017 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Topics: Antibodies, Monoclonal; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prospective Studies; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Young Adult | 2014 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2016 |
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized control
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Protocols; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Time Factors; Treatment Outcome | 2014 |
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; ErbB Receptors; Female; Head and Neck Neoplasms; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Double-Blind Method; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; International Cooperation; Kaplan-Meier Estimate; Lapatinib; Maintenance Chemotherapy; Male; Middle Aged; Molecular Targeted Therapy; Odds Ratio; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Double-Blind Method; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2011 |
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Neoplasm Recurrence, Local; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
35 other study(ies) available for quinazolines and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Evaluation of the Efficacy of Saracatinib-Loaded Nanoparticles in Lymphatic Metastases of HNSCC with the Aid of Bioluminescence Imaging.
Topics: Animals; Benzodioxoles; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Lymphatic Metastasis; Mice; Nanoparticles; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2022 |
Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodioxoles; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gold; Head and Neck Neoplasms; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Quinazolines; Spectrum Analysis, Raman; Squamous Cell Carcinoma of Head and Neck; Tyrphostins | 2020 |
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2019 |
The Selection of NFκB Inhibitors to Block Inflammation and Induce Sensitisation to FasL-Induced Apoptosis in HNSCC Cell Lines Is Critical for Their Use as a Prospective Cancer Therapy.
Topics: Amides; Anti-Inflammatory Agents; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Fas Ligand Protein; Head and Neck Neoplasms; Humans; Hydrocortisone; Interleukin-8; NF-kappa B; Phenyl Ethers; Pyrimidines; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Tumor Necrosis Factor-alpha | 2019 |
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chlorophyllides; DNA Damage; DNA-Activated Protein Kinase; Down-Regulation; Drug Therapy, Combination; ErbB Receptors; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Photochemotherapy; Photosensitizing Agents; Piperidines; Porphyrins; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
Topics: Afatinib; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Heterografts; Humans; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Quinazolines; Receptor, ErbB-2; Squamous Cell Carcinoma of Head and Neck; Transcription Factors | 2013 |
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Topics: Autophagy; Carcinoma, Squamous Cell; Cytoprotection; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; HEK293 Cells; Humans; NADPH Oxidase 4; NADPH Oxidases; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2013 |
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors | 2013 |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Mice; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sensitivity and Specificity; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transfection | 2014 |
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Topics: Afatinib; Animals; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Phenotype; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured | 2014 |
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Monensin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2014 |
Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Dual-Specificity Phosphatases; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organophosphates; Panitumumab; Phosphorylation; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2014 |
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2015 |
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Knockout; Mice, Nude; Myeloid Differentiation Factor 88; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Cells, Cultured | 2015 |
ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Topics: Anoctamin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chloride Channels; ErbB Receptors; Fusion Regulatory Protein 1, Heavy Chain; Gefitinib; Head and Neck Neoplasms; HEK293 Cells; Humans; Multiprotein Complexes; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2015 |
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck | 2016 |
Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Head and Neck Neoplasms; HEK293 Cells; Humans; Mice; Multigene Family; Mutation; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-4; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2016 |
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection | 2016 |
Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Head and Neck Neoplasms; Humans; Mutant Proteins; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Rotenone; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tyrphostins | 2017 |
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays | 2011 |
Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Radiation; Epidermal Growth Factor; ErbB Receptors; Flavonoids; Gamma Rays; Head and Neck Neoplasms; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Tyrphostins | 2011 |
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2012 |
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.
Topics: Adolescent; Adult; Carcinoma, Squamous Cell; Cell Culture Techniques; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Young Adult | 2013 |
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mutation; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Quinazolines; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2012 |